In his virtual conference presentation last week Graham gave an estimate of expected timelines for results from the clinical trials currently programmed.
Below are some brief transcribed extracts from the presentation, with indicated time points. Quarters referred to relate to the 2021 calendar year.
RECCE327 Intravascular Infusion for Sepsis
7:50 min: “First in-human dosing occurring in the very near months in an Adelaide hospital or an Adelaide clinical trial facility, with near-term data points available call it Q2-Q3 over the time ahead.”
RECCE327 Topical Administration for Infected Burns
8:10 min: “Former Australian of the Year Professor Fiona Wood and her colleagues at a leading teaching hospital are utilising that compound as we speak, and that is focused on a broad spectrum nature of bacterial infections – gram-positive and gram-negative and superbugs.
That hopefully in parallel with the intravascular infusion program should provide some globally meaningful real clinical insights as to what may be clinically possible with this compound in what is a Phase1/Phase2 trial in Australia.”
RECCE435 Helicobacter pylori (pre-clinical)
17:00 min: “We are in the middle of our clinical studies with that institute, with a focus on Q4 all going well being available for Phase1 or Phase2 treatment in humans.”
RCE Price at posting:
$1.01 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)